Health Care [ 6/12 ] | Pharmaceuticals [ 30/74 ]
NASDAQ | Common Stock
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 18, 24 | -0.72 Increased by +73.57% | - |
| Aug 13, 24 | -0.68 Increased by +81.61% | - |
| Apr 16, 24 | -2.42 Increased by +30.46% | -2.63 Increased by +7.98% |
| Jan 6, 24 | -2.42 Decreased by -34.44% | -2.63 Increased by +7.98% |
| Nov 20, 23 | -2.74 Decreased by -2.39 K% | -3.12 Increased by +12.18% |
| Aug 14, 23 | -3.68 Decreased by -1.32 K% | -3.32 Decreased by -10.84% |
| May 12, 23 | -3.48 Decreased by -3.77 K% | -3.60 Increased by +3.33% |
| Mar 1, 23 | -1.80 Increased by +30.77% | -0.12 Decreased by -1.40 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -4.87 M Increased by +53.78% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -3.93 M Increased by +72.12% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 109.73 K Increased by +N/A% | -2.85 M Increased by +58.10% | Decreased by -2.60 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -11.06 M Decreased by -62.37% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.53 M Decreased by -23.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -14.08 M Increased by +29.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -6.81 M Increased by +30.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -6.81 M Increased by +30.02% | Decreased by N/A% Decreased by N/A% |